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Background: Human Immunodeficiency Virus 1 (HIV-1) exhibits a wide range of interactions with the host cell but
whether viral proteins interact with cellular RNA is not clear. A candidate interacting factor is the trans-activator of
transcription (Tat) protein. Tat is required for expression of virus genes but activates transcription through an
unusual mechanism; binding to an RNA stem-loop, the transactivation response element (TAR), with the host
elongation factor P-TEFb. HIV-1 Tat has also been shown to alter the expression of host genes during infection,
contributing to viral pathogenesis but, whether Tat also interacts with cellular RNAs is unknown.
Results: Using RNA immunoprecipitation coupled with microarray analysis, we have discovered that HIV-1 Tat is
associated with a specific set of human mRNAs in T cells. mRNAs bound by Tat share a stem-loop structural
element and encode proteins with common biological roles. In contrast, we do not find evidence that Tat
associates with microRNAs or the RNA-induced silencing complex (RISC). The interaction of Tat with cellular RNA
requires an intact RNA binding domain and Tat RNA binding is linked to an increase in RNA abundance in cell lines
and during infection of primary CD4+ T cells by HIV.
Conclusions: We conclude that Tat interacts with a specific set of human mRNAs in T cells, many of which show
changes in abundance in response to Tat and HIV infection. This work uncovers a previously unrecognised
interaction between HIV and its host that may contribute to viral alteration of the host cellular environment.
Keywords: Human immunodeficiency virus, Tat, RNA, Transcription factor, RNA immunoprecipitation, Microarray, T
cell, MicroRNABackground
Like all viruses, HIV-1 depends on the internal envi-
ronment of the host cell to complete its life cycle and
during virus replication a number of interactions occur
between the virus and its host. These include interac-
tions between viral and cellular proteins and viral pro-
teins and host DNA. Whether HIV encodes proteins
that allow interaction with cellular mRNA is unknown.
HIV Tat activates transcription of viral messenger RNA
(mRNA) and genomic RNA from the integrated provirus
and is necessary for HIV replication [1,2]. In the absence
of Tat, RNA polymerase II initiates transcription at the
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article, unless otherwise stated.is blocked, leading to the production of short RNA tran-
scripts [3,4]. This stalled transcriptional state also occurs
in latently infected resting CD4+ T cells [4,5] and is
thought to underlie life-long virus persistence.
Tat localizes to the LTR through an unusual mechanism,
binding to the trans-activation response element (TAR),
an RNA stem loop formed in nascent viral transcripts
[6-8]. Tat binds to TAR with the host elongation factor P-
TEFb through direct interaction with the CyclinT1 subunit
[9-12]. P-TEFb then phosphorylates the RNA polymerase
II C-terminal domain and the repressive factors NELF and
DSIF, allowing transcriptional elongation. Tat also directly
binds and recruits histone acetyltransferases [13] and the
nucleosome remodeling complex SWI/SNF [14,15]. These
changes in chromatin conformation allow full transcrip-
tion of HIV messenger RNA (mRNA) and genomic RNA
and subsequent release of infectious virions.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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http://www.retrovirology.com/content/11/1/53HIV Tat has also been suggested to function as a sup-
pressor of post-transcriptional gene silencing (PTGS)
[16-19], interacting with Dicer [17], but these findings
have not been confirmed by other studies [20,21]. Such ac-
tivity may counter reported repression of HIV replication
by the cellular PTGS pathway [16-19,22-27]. HIV RNA
has been observed to be recruited to cellular mRNA pro-
cessing bodies (P-bodies) [22] and knockdown of RNA in-
duced silencing complex (RISC) and P-body components
[21-24], or inhibition of specific cellular miRNAs [25-27],
have been described to increase HIV RNA abundance and
viral replication. However, a more recent study did not ob-
serve co-localisation of HIV RNA with P-bodies or ob-
serve effects of P-body component knockdown on HIV
replication [28].
In addition to binding to TAR, Tat has the potential to
interact with host RNAs but whether this occurs in cells
is unknown. Although the high affinity of Tat for TAR
requires the stem-loop structure and a bulge of unpaired
nucleotides present on the 5’ side of the loop, Tat can
tolerate a range of mutations to the TAR sequence
[29,30] and this may allow interaction with host RNA to
occur in cells. Consistent with this possibility, Tat has
been reported to bind to 3 cellular mRNA molecules, all
in vitro. Recombinant Tat binds to a predicted stem loop
at the 5’ end of IL6 mRNA in vitro and this sequence is
necessary for Tat-mediated increase in IL6 RNA in vivo
[31]. Similarly, recombinant Tat binds TLR4 RNA in vitro
[32], Tat-containing cell lysate shifts a SOD2 RNA probe
[33] and Tat-mediated activation of LTA (TNFβ) requires
the presence of a predicted stem-loop structure at the 5’
end of its mRNA [34].
Expression of HIV Tat in cells leads to changes in cellu-
lar gene expression that often mirror the changes that
occur during HIV infection [35-39]. Given that Tat has
also been reported to interact with a wide range of cellular
proteins, including components of the basal transcription
machinery [40,41], transcription factors [42,43], chromatin
regulators [44,45], anti-viral factors [46,47], and cell sur-
face receptors [48,49], it is unclear whether effects of Tat
on the levels of cellular mRNAs reflect direct Tat-RNA
interactions.
Considering that Tat is an RNA binding protein and that
it can alter cellular RNA abundance, we hypothesized that
Tat binding to human RNA might represent an uncharac-
terized interaction between HIV and its host. We report
here experiments revealing that HIV Tat associates with a
specific set of cellular mRNAs in T cells.
Results
Tat associates with human mRNA in T cells
We hypothesized that Tat interacts with human RNA in
HIV-1 target cells. To test this, we generated human T
cell lines in which HA or FLAG epitope-tagged Tat isstably expressed under the control of the HIV-1 LTR
(Figure 1A). Expression from the HIV-1 LTR ensures
physiological levels of Tat expression (Figure 1B) and
epitope-tagging does not alter protein activity (Figure 1C).
Tat was then immunoprecipitated (IP) with anti-HA or
anti-FLAG antibodies and bound RNAs purified. Enrich-
ment of TAR, encoded by the HIV-1 LTR, in the IP could
be measured by quantitative polymerase chain reaction
(Q-PCR) and acted as a positive control for the assay
(Figure 1D). IP from HA-Tat cells with anti-FLAG anti-
body, or from FLAG-Tat cells with anti-HA antibody, did
not result in significant RNA purification, demonstrating
that both antibodies specifically enrich for Tat. We could
also detect enrichment of cellular 7SK RNA (Figure 1D),
with which Tat associates through P-TEFb [50].
To identify human mRNA associated with Tat, we differ-
entially labelled IP-enriched mRNA and total cellular
mRNA and hybridized these together to a microarray con-
taining multiple probes for all human RefSeq transcripts.
The array also contained probes for HIV RNA, which con-
firmed enrichment of TAR by Tat IP (Figure 1E). Because
only poly-adenylated RNAs are labelled for the array ana-
lysis (due to the use of oligo-dT to prime cDNA synthesis),
this detection of Tat binding to TAR demonstrates that Tat
remains associated with HIV RNA after poly-adenylation
has taken place. We then analysed the data from the hu-
man RNA probes. Comparison of HA Tat and FLAG Tat
RNA IPs revealed a significant overlap between the cellular
RNAs enriched in both experiments (Figure 2A). Requir-
ing at least two probes to report significant enrichment in
the IP RNA fraction, we identified a total of 317 cellular
mRNAs associated with Tat in both HA and FLAG IPs (of
16,538 mRNAs present on the array, Additional file 1).
Therefore, in addition to binding to TAR, Tat also interacts
with host RNAs. Furthermore, rather than binding to all
mRNAs, Tat binds to a specific set of transcripts. This set
of RNAs bound by Tat included those encoding for ISG20,
JUN, DNAJB2, FADD, TNFRSF8 and OAS3, expression of
which have previously been shown to be regulated by Tat
[35-39]. The inclusion of genes previously found to be reg-
ulated by Tat provides confidence in our data and suggests
that Tat may mediate changes in RNA abundance through
direct interaction with specific mRNA species.
We swapped labelling dyes to ensure that the apparent
enrichment of cellular RNA was not due to biases in dye
incorporation; 83% of RefSeq mRNAs identified in the ori-
ginal Tat RNA IPs were also identified in this dye-swap ex-
periment (Figure 2B). To further verify that Tat specifically
interacted with these cellular RNAs, we labelled the RNA
purified in our control IP experiments (anti-HA IP from
FLAG-Tat cells, anti-FLAG IP from HA-Tat cells and con-
trol Rat IgG IP from HA-Tat cells). Unlike Tat-enriched
RNA, the small amounts of RNA enriched by these con-
trol IP experiments did not produce material sufficient for
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Figure 1 A system for identifying human RNAs bound by HIV Tat. A. HA or FLAG-tagged Tat was stably expressed from the HIV LTR as part
of a bicistronic transcript with a G418 resistance gene in CEM T cells. Tat protein bound to the TAR stem-loop present at the 5’ end of the
transcript. B. Western blotting for HA-Tat in CEM HA-Tat cells (1/1 and 1/5 dilutions) and in an equal number of C1866 cells 0, 5 and 7 days after
infection with the SF2 strain of HIV engineered to encode HA-tagged Tat. C. Activity of untagged and HA-tagged Tat measured by GFP expression
from the HIV LTR in the GHOST reporter line using flow cytometry. D. Enrichment (mean and SD) of TAR-Tat construct, 7SK and GAPDH RNA in
HA-Tat and FLAG-Tat IPs compared to input RNA measured by Q-PCR. 7SK is enriched by 9-fold (SD 3.8) by IP for HA-tagged Tat and 3.6-fold
(SD 0.73) by FLAG-tagged Tat. In comparison, GAPDH RNA is enriched by 0.2-fold (SD 0.007) and 1.14-fold (SD 0.25), respectively. Enrichment of
7SK compared to GAPDH is significant for both HA and FLAG IPs (p = 0.017 and 0.0051, respectively, t-test, n = 3). The enrichment in control IPs
where the antibodies were switched are shown for comparison (white bars). E. Enrichment (mean and SD) of poly-adenylated TAR-Tat construct
RNA in HA-Tat and FLAG-Tat IPs relative to input RNA measured using microarrays.
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http://www.retrovirology.com/content/11/1/53hybridisation according to the standard protocol. However,
to confirm that even this small amount of control IP ma-
terial did not exhibit enrichment for Tat-associated RNAs,
we hybridized the labelled RNA to the arrays. The use of
cluster analysis to compare these data to our three Tat
RNA IP experiments demonstrated that control IPs pro-
duce distinct patterns of enrichment that do not correlate
with the RNAs enriched by Tat IP (Figure 2B).
We next sought to verify the array results by measuring
enrichment of individual RNAs by Q-PCR (Figure 2C).
We noted that RNAs encoding ISG20 and the apoptosis
mediators TNFRSF8 (CD30) and FADD, previously shown
to be upregulated by HIV Tat [36,39], were bound by Tat
in both array experiments. QPCR for TNFRSF8, FADD
and ISG20 mRNA in replicate HA and FLAG Tat IPs con-
firmed enrichment of these RNAs compared to GAPDH
mRNA. Also consistent with the array data, qPCR for
HPRT1 mRNA showed that this was not enriched com-
pared to GAPDH mRNA (between 0.2-1-fold). The arrays
therefore accurately report enrichment of specific mRNAs
in Tat IP fractions.
There is a potential with native RNA IP experiments
that proteins form new interactions with RNA after cell
lysis that did not occur in the intact living cell. To test
whether Tat also interacted with human RNAs within in-
tact cells, we repeated the RNA IP after crosslinking the
cells with formaldehyde (Figure 2D). These experimentsshowed that FADD and TNFRSF8 remain enriched in IPs
from crosslinked cells and therefore that Tat interacts with
these RNAs in living cells.
Tat-associated human RNAs are enriched for specific
functions
We next used Gene Ontology to explore whether the set
of RNAs that interact with Tat had any functions in com-
mon (Figure 2E). To provide robust statistics for this as-
sessment, we used cluster analysis to identify a larger set
of 2000 RNAs enriched in both HA and FLAG RNA IPs
and a control set of 2000 RNAs depleted in HA and FLAG
IPs. Gene categories specifically enriched in the set of Tat-
associated RNAs included nucleotide binding and the
overlapping categories transferase activity, tRNA meta-
bolic process and ligase activity. Indeed, this set of RNAs
included 26 of the 34 enzymes that constitute the KEGG
aminoacyl-tRNA biosynthesis pathway (Additional file 2).
The enrichment of mRNAs encoding shared functional
annotations suggests that they may share specific se-
quence or structural features or a common RNA binding
protein that mediates interaction with HIV Tat.
Tat does not associate with miRNAs
The results described above show that HIV Tat associates
with specific mRNAs. Tat has been reported to interact
with exogenously expressed Dicer [17] and TAR is
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Figure 2 Tat interacts with human mRNA in cells. A. Venn diagram showing cellular RefSeq mRNAs enriched by IP for HA-Tat or FLAG-Tat.
The overlap between the two sets of RNAs is significant at p < 10−16 (Hypergeometric). B. Clustered heat-map of the RNA IP data. Fold-
enrichment of mRNA in the IP fraction relative to input RNA is shown as shades of blue, according to the scale below. Samples (columns) and
mRNAs (rows) are clustered by their enrichment pattern with genes and samples with similar patterns of enrichment grouped together. The
numbers 1–4 signify the 4 different probes present on the arrays used to measure enrichment by HA and FLAG-Tat IP. The arrays used for the
other experiments only contain probe number 4. The similarities between the pattern of RNA enrichment for each experiment is related by the
tree shown above. C. Enrichment (mean and SD) of the human mRNAs FADD, ISG20 and TNFRSF8 in replicate HA-Tat and FLAG-Tat IPs relative to
GAPDH mRNA, measured by Q-PCR. An additional negative control, HPRT mRNA, was enriched between 0.2-1-fold. D. Enrichment (mean and SD)
of the human mRNAs GAPDH, FADD, ISG20 and TNFRSF8 in HA-Tat immunoprecipitate from formaldehyde cross-linked cells, measured by Q-PCR.
The p-values for enrichment versus GAPDH were TAR RNA p = 0.0046, ISG20 p = 0.1778, FADD p = 0.0185 and TNFRSF8 p = 0.0395 (t-test, n = 3).
Enrichment of RNA by anti-HA IP from FLAG-Tat cells was performed as a negative control. E. Bonferoni-modified p-value for the association of
functional gene categories with enlarged sets of ~2000 genes enriched or depleted in HA-Tat and FLAG-Tat IPs. .
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http://www.retrovirology.com/content/11/1/53processed into small RNA species [51-54], suggesting
that Tat might also interact with miRNAs, either directly
or through RISC components. To test this, HA-Tat and
FLAG-Tat were immunoprecipitated as before and the IP
RNA labelled and hybridised to miRNA arrays, together
with input and control IP RNA (Figure 3A). As a positive
control, the RISC component Ago2 was precipitated from
FLAG-Tat cells with two independent antibodies. We found
that IP for Ago2 strongly enriched for miRNAs, an average
of 15-20-fold. However, no miRNAs were enriched by IPfor FLAG or HA-tagged Tat and the results were indistin-
guishable from the negative control IP. We conclude that,
contrary to its interaction with host mRNA, Tat does not
interact with host miRNA species.
The lack of association between Tat and miRNAs sug-
gested that Tat does not interact with RISC components.
To confirm this, we immunoprecipitated HA Tat and
tested for co-purifying endogenous Dicer, Ago1 and
Ago2 by western blotting (Figure 3B). We could not de-
tect any of these components of RISC co-precipitating
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Figure 3 Tat does not associate with miRNAs or with RISC
components. A. Clustered heat-map showing the amount of
cellular miRNAs in HA-Tat and FLAG-Tat cells and in Ago2, Tat and
control IgG IP. Ago2 was immunoprecipitated with two different
antibodies (M and S). Samples (columns) and miRNAs (rows) are
clustered by their enrichment pattern. miRNA abundance compared
to the average across all samples is indicated by colour, according
to the scale below (log2 ratio). B. Immunoblotting for Ago1, Ago2,
Dicer and HA-Tat in input and HA-Tat IP lysates from HA-Tat cells
and control FLAG-Tat cells. The position of size markers are illustrated
on the left hand side of each panel.
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http://www.retrovirology.com/content/11/1/53with Tat and, taken together with the miRNA IP data,
this indicates that Tat is not present in a ribonucleopro-
tein complex with RISC in T cells.
The interaction of Tat with cellular RNA depends on its
RNA binding domain
Tat interacts with TAR through an arginine-rich domain
located between amino acids 49 and 57. The association of
Tat with human RNA could therefore occur through dir-
ect interaction through this RNA binding domain. To test
this, we mutated lysines at positions 50 and 51 (K50S-
K51G), which abrogates RNA binding activity [55]. Ex-
pression of this mutant in a LTR-reporter cell line showed
that the K50S-K51G mutation reduced Tat activity by
around 50%, verifying that the mutation compromised Tat
function (Figure 4A). As we were unable to generate stable
lines expressing Tat K50S-K51G, we instead expressed
wild-type and K50S-K51G Tat in the T cell line CEM
using a lentiviral vector. Flow cytometry indicated that the
two viruses infected similar numbers of cells and western
blotting for HA-Tat showed that the mutant form was
expressed at higher rather than lower, levels than the WT
protein (Figure 4B). Cell fractionation into nuclear and
cytoplasmic components indicated that Tat K50S-K51G
could still enter the nucleus, albeit at a slightly lower level(Figure 4C). HA-Tat was then precipitated from the cells
as before and the associated RNA purified and quantified.
We found that the K50S-K51G mutation reduced immu-
noprecipitation of RNA by 85%, down to the level
observed with control non-specific antibody (Figure 4D).
Although the use of transient transduction limited the
number of cells available for analysis, we found that en-
richment of the specific Tat-bound RNAs FADD and
TNFRSF8 by HA IP was also abrogated by the K50S-
K51G mutation (Figure 4E). These data demonstrate that
the interaction of Tat with cellular RNA requires an intact
RNA binding domain.
Enrichment of a stem-loop structure within Tat-bound mRNAs
We next considered whether a sequence or structural
motif could be shared between the set of Tat-bound RNAs,
potentially explaining their shared precipitation by Tat
RNA IP. We first sought to identify significantly enriched
sequence motifs using the tool MEME-ChIP [56]. Analys-
ing the set of RNAs bound in both HA and FLAG-Tat IPs,
we identified 4 motifs that were significantly enriched
(Figure 5A). Motif 2 was judged by MEME to be signifi-
cantly similar to Motif 0 and thus they were grouped to-
gether. Comparison to motifs known to be recognised by
RNA binding proteins [57] within MEME-ChIP failed to
match motifs 0, 2 and 3 but motif 1 was found to be simi-
lar (p = 0.00017) to the motif identified for TRA2 [57],
which regulates pre-mRNA splicing. MAST [58] shows
that the motifs are often present at multiple copies within
the bound RNAs and are distributed across the RNA mol-
ecules, rather than enriched towards the 5’ or 3’ ends
(Additional file 3). Motif 0 is a long sequence with a strik-
ing periodic enrichment for C and G nucleotides. We
considered that this sequence could form a stem-loop
structure. We used FIMO [59] to identify the sequences
within the set of Tat-bound mRNAs that matched Motif 0
and the related Motif 2 and used LocARNA [60] to dis-
cover whether these could be aligned and folded into com-
mon structures. The algorithm found that the sequences
shared stem-loop structures (Figure 5B), which share simi-
larities with TAR, including a bulge that in TAR (at pos-
ition 23) is necessary for Tat binding [29,30]. Thus, the
structure shared between Tat-bound cellular RNAs may
play a role in the interaction with Tat.
Human RNAs bound by Tat increase in abundance during
HIV infection of primary CD4+ T cells
The interaction of Tat with human RNA may have func-
tional consequences. Thus, we next asked whether RNAs
bound by Tat show changes in abundance during HIV
infection of primary CD4+ T cells. CD4+ T cells were
purified from PBMC, activated with anti-CD3 and anti-
CD28 antibodies, expanded with IL2 and then infected
with both non-purified and purified stocks of HIV-1
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Figure 4 The interaction of Tat with human RNA depends on the RNA binding domain. A. Activity of wild-type HA-Tat (white bars) and
HA-Tat K50S-K51G (RNA binding mutant), grey bars) in the LTR reporter cell line GHOST, measured by the proportion of GFP-positive cells (left
panel) and mean GFP intensity (right panel). B. Immunoblotting for HA-Tat and β-actin in CEM cells 72 hours after infection with lentiviral vectors
expressing either GFP alone, GFP and WT HA-Tat or GFP and HA-Tat-K50S-K51G. C. Immunoblotting for HA-Tat, TBP (nuclear protein) and Tubulin
(cytoplasmic protein) in cytoplasmic (C) and nuclear (N) fractions of CEM cells expressing WT HA-Tat or HA-Tat-K50S-K51G. D. Amount of
DNase-treated RNA purified from HA-Tat and control antibody IPs from CEM cells infected with WT-Tat or Tat K50S-K51G encoding lentivirus, as a
percentage of the total RNA in the lysate. Data from 3 independent infections are shown. E. Enrichment (mean and SD) of the human mRNAs
GAPDH, ACTIN, FADD and TNFRSF8 in HA-Tat immunoprecipitate from cells infected with WT HA-Tat or HA-Tat K50S-K51G encoding lentivirus,
measured by Q-PCR.
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http://www.retrovirology.com/content/11/1/53(NL4-3) at a dose of 10 infectious units per cell. RNA
was collected from infected and mock-infected cells at
14, 24 and 48 hours and changes in RNA abundance
compared to uninfected cells measured using microar-
rays. Clustering RNAs by their expression patterns sepa-
rates RNAs that exhibit increases in abundance during
HIV infection from those that exhibit decreases in abun-
dance (Figure 6A, Additional file 4). We observed two
main clusters of RNAs that showed increases in transcript
abundance after HIV infection, one from 14 hours and a
second from 48 hours (labelled A and B in Figure 6A).
Alignment of our Tat RNA binding data with the gene
expression profiling data revealed that Tat was predom-
inantly associated with RNAs that increased in abun-
dance during infection (p = 0.003, hypergeometric) and
was particularly associated with the 48 hour cluster (B
in Figure 6A). Tat-associated RNAs that increased in abun-
dance included TNFRSF8, MAPK12, METRNL, OAS3,
BATF3, PLCG2, LTB, RASGRP2, JUN and PTGER1. In-
creased expression of a number of these genes has previ-
ously been implicated in HIV pathology [35-39].
We sought to characterise the two clusters of upregu-
lated RNAs further to understand the significance of
the association of Tat primarily with the second, latercluster. Gene Ontology revealed that genes in the first
cluster upregulated by 14 hours have functions in the re-
sponse to virus (5-fold enriched, p = 0.002), with the cat-
egories immune response (2.2-fold enriched, p = 0.0014)
and regulation of programmed cell death (2.9-fold,
p = 2.7×10−5) also enriched (Figure 6B and Additional
file 5). Comparison with expression data from T cells ex-
posed to interferon β showed that this cluster corresponds
to the classical cellular interferon response to virus infec-
tion (Figure 6C).
In contrast, genes in the second cluster more strongly
associated with Tat are instead enriched for RNAs encod-
ing proteins with roles in ribosome biogenesis (19-fold
enrichment, p = 6×10−9), RNA metabolic process (8-fold
enrichment, p = 1.2×10−4) and mitotic cell cycle (6-fold en-
richment, p = 1.4×10−5) (Figure 6B and Additional file 5).
Contrary to their upregulation by HIV, these genes are in-
stead downregulated by interferon (Figure 6C) and thus
upregulation would appear to be specific for HIV in-
fection. We considered that upregulation of these genes
normally repressed by interferon might reflect an ability
of Tat to counteract the normal interferon-stimulated
response. However, gene expression changes induced by
interferon in Tat-expressing CEM cells were similar to
Figure 5 Sequence motifs and stem-loop structures enriched in Tat-bound RNAs. A. Sequence motifs significantly enriched within the set
of Tat-bound mRNAs generated by MEME-ChIP. The numbering of the motifs (0 to 3) is ordered by their significance, with the E-values shown to
the right. The motifs are represented as logos with the height of the letter representing the probability of the base at that position multiplied by
the total information content of the position. Motifs 0 and 2 were determined by MEME-ChIP to be statistically similar and are aligned. Motif 1
was judged by MEME-ChIP to be similar to that of the splicing factor TRA2 (aligned). B. The consensus structure of all sequences that match
motifs 0 and 2, determined by LocARNA. The structure of TAR (from [30]) is shown for comparison.
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clude that Tat interacts with a specific set of cellular RNAs
that are upregulated during HIV infection.
Interaction with HIV Tat is associated with an increase in
RNA abundance
The upregulation of Tat-associated genes during HIV infec-
tion suggests that this increase in RNA abundance occurs
due to Tat. To test this, we examined the abundance of
mRNAs in CEM cells stably expressing Tat compared with
the parental CEM cell line and a CEM line stably express-
ing GFP, selected in parallel. We found that although the
majority of Tat-associated mRNAs did not show changes in
abundance in cells expressing Tat, significantly more
RNAs exhibited an increase in abundance than expected
by chance (n = 23, p < 0.001, Hypergeometric; Figure 6D,Additional file 7). RNAs bound by Tat that also increased
upon expression of Tat included TNFRSF8, ISG20,
MAPK12, METRNL and DNAJB2, all of which are also
upregulated during HIV infection (Additional file 4,
[35-39]). In contrast, there was no significant relationship
between Tat binding and decreases in transcript abundance
(n = 5, p = 0.95, Figure 6D). Furthermore, there was no
relationship between the RNAs detected in control IPs
and changes in RNA abundance in Tat-expressing cells
(p = 0.178).
We next considered whether Tat RNA binding activity
was necessary for increases in RNA abundance. We con-
structed two stable cell lines, in which expression of either
WT Tat or the Tat RNA binding mutant K50S-K51G
could be induced by treatment with Doxycycline and mea-
sured RNA abundance using gene expression microarrays
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Figure 6 RNAs associated with Tat show increases in transcript abundance. A. Clustered heat-map showing changes in RNA abundance in
primary CD4+ T cells after mock infection or infection with purified or unpurified HIV (NL3-4) at 14, 24 and 48 hours, relative to uninfected cells at
the same time point. Shades of red indicate increases in RNA abundance and shades of green indicate decreases in RNA abundance, according
to the scale below (log2 ratio). RNAs associated with Tat are marked by blue lines at the right hand side. B. Genes with functions in selected Gene
Ontology categories are marked with a blue line. Data are aligned with A. C. Changes in RNA abundance in primary CD4+ T cells after addition of
interferon-beta (400 U/ml) for 4 hours compared to untreated cells. Data for 3 replicate experiments are shown aligned with A. D. RNAs that
increase in abundance (top) and decrease in abundance (bottom) by at least 1.5-fold in CEM cells stably expressing HA-Tat compared to parental
CEM cells and CEM cells stably expressing GFP. The relative abundance of each RNA is represented by colour, according to the scale below
(log2 ratio). RNAs associated with Tat are marked by blue lines at the right hand side. E. RNAs that increase in abundance (top) and decrease in
abundance (bottom) in cells expressing WT HA-Tat compared to cells expressing the RNA binding mutant HA-Tat K50S-K51G. The 1000 RNAs with
highest and lowest relative expression in WT Tat cells compared to K50S-K51G cells are shown. The relative abundance of each RNA (log2(WT-Tat
vs Tat K50S-K51G) is represented by colour, with log2 ratios marked on the left. RNAs associated with Tat are marked by blue lines at the right
hand side.
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hibited changes in RNA abundance compared with cells
expressing Tat K50S-K51G, with a greater number of
genes showing increased expression in the WT Tat cells
(Figure 6E). Furthermore, changes in RNA abundance
were correlated with detection of Tat binding to the
RNA, with Tat being bound more frequently to the set
of RNAs exhibiting increased abundance in WT Tat
cells compared to RNAs that exhibited decreased abun-
dance. We conclude that Tat RNA binding is required
for Tat to increase RNA abundance.
Discussion
Although many interactions between HIV and host cell
proteins have been described, whether the virus interacts
with cellular RNAs was unknown. We have discoveredthat HIV Tat interacts with a set of cellular mRNAs in hu-
man T cells. These interactions are specific because they
can be detected using two different epitope tags, they are
not observed in control IPs, and the interactions can be
verified by Q-PCR. The interaction of Tat with cellular
RNA depends on lysine residues within the RNA binding
domain known to be important for interaction with TAR.
We could not detect association of Tat with miRNAs or
with protein components of RISC. The cellular mRNAs
bound by Tat are associated with specific molecular func-
tions and share predicted stem-loop elements. Tat expres-
sion and HIV infection frequently results in an increase in
the abundance of Tat-bound RNAs.
Tat has previously been shown to interact with three
human RNAs by gel-shift assays in vitro [31-33] but
such experiments lack specificity and whether these few
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was not clear. The system we have developed, in which
RNA is purified from immunoprecipitated Tat tagged
with independent epitopes and expressed from its own
promoter, allowed us to detect the specific interactions
between physiological levels of Tat and cellular RNA as
they occur in cells. Indeed, although these experiments
show that Tat interacts with a select set of human RNAs
in cells, we could not detect an interaction between Tat
and the RNAs with which it has previously been re-
ported to interact in vitro [31-33].
Tat binding to TAR tolerates mutations to the stem and
loop and, although the bulge structure at position +23 is
required, Tat recognises a number of variants [29,30]. Tat
also binds related structures predicted to form within the
IL6 and TLR4 mRNAs [31,32]. Analysis of motifs signifi-
cantly enriched in the set of Tat-bound RNAs revealed a
striking palindromic GC rich motif that is predicted to
fold into stem-loop structures similar to TAR (Figure 5).
We found that these motifs were located throughout Tat
target RNAs, rather than being located in at the 5’ end as
for TAR. Therefore, if Tat does recognise such RNA ele-
ments, they are unlikely to function in the same way as
TAR in the activation of transcriptional elongation. Identi-
fication of Tat-RNA UV-crosslink sites at high-resolution
using sequencing-based methods such as iClip or PAR-
Clip [61] will confirm whether Tat is binding to these ele-
ments and whether this occurs in live cells. Their import-
ance for Tat binding could then be tested through the
expression of RNAs in which such structures are dis-
rupted by mutation.
Tat has previously been shown to cause changes to hu-
man gene expression and some of these changes have
been linked to HIV pathology [35-39]. How Tat mediates
such changes in RNA abundance is unclear. In addition
to being an RNA binding protein, Tat has also been re-
ported to interact with a great many proteins, from tran-
scription factors to cell surface receptors [40-49], and so
Tat-mediated changes in gene expression could theoret-
ically be due to these interactions rather than Tat RNA
binding function. Arguing against this, we have identi-
fied a global association between Tat binding to cellular
mRNAs and an increase in RNA abundance. Firstly, a
number of RNAs previously shown to be upregulated by
HIV and by Tat are also bound by Tat, including ISG20,
JUN, DNAJB2, ISG20, MAPK12, METRNL, TNFRSF8
and OAS3. Secondly, Tat is associated with a cluster of
RNAs upregulated during HIV infection. Thirdly, we de-
tect Tat binding at a significant number of the RNAs
that increase in abundance in Tat-expressing cells. Fi-
nally, mutations that block Tat RNA binding activity
counteract these increases in RNA abundance. Thus, the
association of Tat with specific mRNAs provides a direct
link between Tat and changes in RNA abundance duringHIV infection that is parsimonious with its core RNA bind-
ing function. Tat binding to host RNA may act to recruit or
displace a cellular factor or otherwise alter mRNA transcrip-
tion, processing, export or stability. Further experiments will
be required to identify the mechanism through which Tat
RNA binding leads to changes in cellular mRNA abundance.
Early studies of Tat function considered the hypothesis
that Tat might counteract the host interferon response [62]
and there is some evidence Tat can regulate interferon tar-
get genes. Treatment of cells with recombinant Tat has
been suggested to suppress IFNγ signaling through upregu-
lation of SOCS2 [63] and Tat has been reported to interact
with PKR, modulating its function [64]. Expression of Tat
in dendritic cells leads to induction of interferon-inducible
genes encoding T cell chemo-attractants, luring these target
cells to sites of infection [36]. We thus examined whether
Tat bound to interferon-regulated RNAs, and whether the
presence of Tat altered the transcriptional response to
interferon-β in our T cell line model. However, we did not
find evidence that Tat RNA binding acts to modulate the
transcriptional response to interferon (Additional file 6).
Although we could detect interaction of Tat with TAR
and cellular mRNAs and detect interaction of Ago2 with
miRNAs, we could not detect interaction of Tat with cel-
lular miRNAs. This suggests that Tat either does not inter-
act with miRNAs or that the interaction occurs at a low
level beyond our detection. Consistent with the lack of de-
tected Tat-miRNA interactions, we also failed to identify
an interaction between Tat and endogenous Dicer, Ago1
or Ago2. Tat has previously been reported to directly
interact with exogenously expressed Myc-tagged Dicer
[17], but interaction with the endogenous protein has not
been described. Whether or not Tat inhibits RNA silen-
cing is also unclear; some studies report that Tat can re-
press small RNA generation [16-19], but others have been
unable to confirm this [20,21]. Our data indicate that if
Tat does act to inhibit PTGS, it is unlikely to do so
through an association with cellular miRNAs.
Our discovery that Tat targets a specific set of cellular
RNAs presents a new interface through which HIV can
interact with its host. In addition to Tat, HIV encodes two
other RNA binding proteins, Rev and nucleocapsid, which
may also interact with cellular RNAs in addition to their
viral targets. A number of other viruses encode RNA bind-
ing proteins that may also target specific cellular RNAs.
For example, Hepatitis C virus (HCV) NS5a binds to the
3’-ends of HCV plus and minus strand RNAs and functions
in genomic RNA replication but has also been implicated
in the regulation of host genes, including upregulation of
IL8 and LTB [65,66]. Influenza NS1 interacts with viral
mRNAs encoding M1 and NS1 but can also interact with
polyA RNA, dsRNA and human U6 and U6atac snRNAs,
functioning to inhibit pre-mRNA splicing, 3’-end process-
ing and mRNA export (reviewed in [67]). Epstein-Barr
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allow export from the nucleus but also interacts with
cellular STAT1 mRNA, inducing a splicing reaction that
leads to production of the STATβ isoform that can act
as a dominant-negative suppressor of STAT1α [68]. The
methods we have presented here could be used to deter-
mine whether these viral factors and others also interact
with a specific set of host RNAs.
The mRNAs bound by Tat encode a set of proteins
enriched for specific functions including nucleotide bind-
ing and tRNA metabolic processes. It is unclear why HIV
Tat should target these RNAs in particular but similar
functional classes of gene are also upregulated upon HIV
infection (Figure 6B and Additional file 5). This may re-
flect the virus’s need to create an environment in which
large amounts of viral genomic RNA and proteins can be
efficiently synthesised. As such, the interaction of Tat with
specific cellular RNAs may have been selected during evo-
lution because it aids HIV replication. Alternatively, inter-
actions between Tat and cellular RNAs may instead
represent off-target effects of Tat’s TAR binding function
that offers no selective advantage to the virus. Either way,
the interaction of Tat with cellular RNA likely has conse-
quences for the host cell. Further studies will be required
to determine whether the association of Tat with specific
cellular RNAs promotes virus replication or pathogenesis.
Conclusions
We have discovered that HIV Tat interacts with a specific
set of cellular mRNAs. These interactions are detected re-
gardless of the antibody used to purify Tat and occur when
Tat is expressed at physiological levels. Tat does not inter-
act with cellular miRNAs or with RISC components. Tat
binding is linked to increases in mRNA abundance, both
in Tat-expressing cells and during HIV infection of pri-
mary CD4+ T cells. The interaction of Tat with human
RNA reveals a new interaction between HIV and its host.
Given Tat’s pleiotropic effects on the host cell, this has im-
plications for the pathology of this important viral agent.
The interaction between viral proteins and host RNA may
in future prove to be a common feature of virus infection.
Methods
Cells lines and plasmids
The promoter in pIRESneo3 was replaced by the LTR
from HIV SF2 and HA or FLAG-tagged 101-amino acid
Tat (from SF2) inserted downstream (before IRES-G418R).
These constructs were transfected into CEM cells and
stable lines selected. For RNA IP experiments measuring
the role of Tat RNA binding function, HA-Tat was cloned
into the pHR-SIN-CSGW-EGFP lentiviral expression con-
struct [69] in which the EGFP cassette was replaced
by IRES-emGFP and K50S-K51G mutations made by
site-directed mutagenesis (Stratagene). The vectors weretransfected into 293T cells together with the packaging
plasmids pMDG and p8.91 and virus harvested, concen-
trated and titred on CEM cells. CEM cells were infected
with the viruses with an MOI of 10. To quantify the ex-
pression in CEM cells relative to HIV infected cells, the
HA tag was also inserted into the 5’ end of Tat in the
p9B18 clone of HIV strain SF2. To compare changes in
RNA abundance associated with Tat RNA binding activ-
ity, HA-Tat and HA-Tat K50S-K51G were cloned into
pTRE2Hyg (Clontech), transfected into Jurkat Tet-On
cells and stable lines selected.HIV infection of primary CD4+ T cells
pNL4-3 encoding the NL4-3 strain of HIV was trans-
fected into 293T cells and virus purified by pelleting
through sucrose and titred on GHOST cells. CD4+ T
cells were purified from PBMC (Buffy coat) by negative
selection (Miltenyi), activated with anti-CD3 and anti-
CD28 (1ug/ml) for 60 hours and then expanded in IL2
(5 ng/ml) for 48 hours. Cells were then split and in-
fected with unpurified NL4-3 (contained within 293T
cell supernatant), NL4-3 purified on a sucrose cushion
(both with a dose of 10 infectious units per cell) or
mock-infected by addition of 293-conditioned media.
Virus was spinoculated at 1000 g for 1 hour and infec-
tion was allowed to proceed for 1 hour at 37°C. Virus
was then washed off the cells and the cells incubated in
fresh media. Cells were harvested in TRIzol (Invitrogen)
at 14, 24 and 48 hrs after infection. We used purified
HIV virus in addition to non-purified virus so we could
filter out expression changes in the recipient T-cells po-
tentially induced by cytokines secreted by the producer
293T cells. In fact, we didn’t observe any significant dif-
ferences in the response to the two viral stocks and so
both datasets were used in the analysis. After activation,
non-infected primary CD4+ T cells were also treated by
addition of interferon-beta (400 U/ml) for 4 hours.RNA IP
CEM cells expressing HA or FLAG-tagged Tat were lysed
(10 mM Hepes, 100 mM KCl, 5 mM MgCl2, 0.5% NP-40,
1 mM DTT, Complete protease inhibitor (Roche) and
RNaseOUT (Invitrogen)) and the nuclei sheared through
a 27-guage needle and by freeze-thawing, as described
[70]. The lysates were then DNase treated (Ambion) on
ice for 30 mins, diluted in NT buffer (50 mM Tris pH7.5,
150 mM NaCl, 1 mM MgCl2, 0.05% NP-40, supplemented
as before) and insoluble material removed by centrifuga-
tion. Lysates were precleared with protein-G beads (Dynal)
and Tat IP performed with anti-HA (3F10; Roche) or anti-
FLAG (M2; Sigma) antibody. Beads were washed 4 times
with NT2 and twice with NT2 containing 1 M urea. Total
RNA was purified from beads and input cell lysate with
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verified using an Agilent Bioanalyzer.
CEM cells crosslinked with 1% formaldehyde were
lysed in ChIP lysis buffer [70] in the presence of RNase-
OUT, sonicated at 9 W for 3 mins (20s pulses) and in-
soluble material removed by centrifugation. The lysate
was precleared and then incubated with 3F10 or control
Rat IgG (Santa Cruz) for 16 hours. The beads were
washed as described [70] and the crosslinks reversed by
incubation at 65°C for 1 hour. RNA was then purified
with TRIzol LS and DNaseI treated.
Microarray analysis of RNA IP samples
200 ng of IP or input RNA were labelled using Agilent’s
QuickAmp labelling kit and hybridized to DNA microar-
rays (Agilent). Initial HA-Tat and FLAG-Tat IPs were
hybridized to a custom microarray containing multiple
probes to all RefSeq mRNAs (includes standard Agilent
probes) [70]. For these custom arrays, RefSeq mRNAs
with at least one probe with an IP/input ratio above
2-fold and p-value < 0.001 and at least one other with an
IP/input ratio above 1.5-fold and p-value < 0.001 were
judged to be enriched by the IP. Subsequent dye-swap
and control IPs were analysed using catalogue Agilent
44K human gene expression arrays (AMADID 014850).
For these arrays, the ratio and p-values were averaged
for RefSeq mRNAs with multiple probes and then those
mRNAs with an IP/input ratio above 2 and p-value < 0.001
were judged to be enriched by the IP. Log2 IP/input ratios
were filtered to remove those with insignificant p-values
and the remaining data clustered using average-linkage
hierarchical clustering. A total of 3 Tat RNA IP microarray
experiments were performed.
miRNA arrays
100 μg of input and IP RNA was labelled and hybridized
to Agilent human miRNA arrays following the standard
protocol. The log2 ratio of the miRNA signal to the geo-
metric mean signal across all samples was calculated and
samples and miRNAs clustered by average-linkage hier-
archical clustering.
Gene expression analysis
Total RNA was purified from cells using Trizol, DNase
treated (Ambion) and integrity confirmed. The HIV sam-
ples were hybridized together with reference RNA (Strata-
gene). The expression ratio between infected cells and
untreated cells at the same timepoint was calculated, data
for genes with multiple probes averaged and probes filtered
for those exhibiting at least 1 absolute log2 expression ratio
above 1. The CEM cell line material was hybridized to-
gether with RNA from the parental CEM line. Genes were
judged to be differentially expressed if HA-Tat/CEM and
HA-Tat/GFP were both above 1.5 or both below 0.66. Tatexpression was induced in Jurkat cells with 1 μg/ml Doxy-
cycline for 48 hours and hybridised with RNA from un-
treated cells. Gene Ontology analysis was performed using
DAVID [71].
Q-PCR
cDNA was synthesized with Superscript II (Invitrogen) and
random primers. Primer and probes were from Applied Bio-
systems; FADD (Hs00356603_g1), ISG20 (Hs00158122_m1),
TNFRSF8 (Hs01114493_m1) and HPRT1 (4333768) or
custom synthesized; TAR (F:GCTAACTAGGGAACC
CACTGCTT, R: CAACAGACGGGCACACACTACT,
Probe: AGCCTCAATAAAGCTTGCCTTGAGTGCTTC),
GAPDH (F: GGCTGAGAACGGGAAGCTT, R:AGG
GATCTCGCTCCTGGAA, Probe: TCATCAATGGAA
ATCCCATCACCA), 7SK RNA (F:AGAACGTAGGG
TAGTCAAGC, R:AGAAAGGCAGACTGCCACAT).
Co-immunoprecipitation, cell fractionation and
immunoblotting
Cells were washed in PBS and lysed with 40 mM Tris
pH 7.5, 150 mM NaCl, 10% glycerol, 0.3% NP-40 con-
taining Complete protease inhibitors (Roche) for 20 min,
and insoluble material removed by centrifugation. Super-
natants were incubated with anti-HA (3F10) antibody
bound to magnetic beads at 4°C for 16 hrs. Beads were
then washed successively in IP buffer, IP buffer contain-
ing 300 mM NaCl, IP buffer containing 500 mM NaCl
0.1% NP-40, and then with 20 mM Tris–HCl pH 8.0,
150 mM NaCl, 10% glycerol. Lysates were separated by
SDS-PAGE and proteins detected with the following
antibodies: HA-Tat (Roche 3F10), FLAG (Sigma M2),
TBP (Abcam ab818), Tubulin (Sigma T4026), Dicer
(Abcam ab14601), Ago1 (Millipore 07–599) and Ago2
(Millipore 07–590). CEM cells were fractionated in nu-
clear and cytoplasmic fractions as described [72].
Motif discovery
The set of 317 enriched mRNAs in both HA and Tat
RNA IP were filtered to contain one transcript per gene
(the longest transcript was selected) and run through
MEME-ChIP [56] with the default options, except for
scan given strand only, any number of repetitions per se-
quence, maximum width of 60, and compare to the
motif database of Ray et al. [57]. The distribution of mo-
tifs across the RNAs was determined using MAST [59],
with an E-value of 1 and the options: use individual se-
quence composition, ENSEMBL homo sapiens database,
scale motif display threshold and no treatment of reverse
complement strands. To identify sequences within the
bound RNAs that match the discovered motifs, we used
FIMO [60] with the ENSEMBL homo sapiens database
and scan given strand only option. We then selected
the 143 sequences matching with motif 0 with a
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motif 2 with p < 10−6, and aligned these with
LocARNA, using the global option [61]. The consensus
structures identified by LocARNA were then visualised
with Pseudoviewer [73].
Availability of supporting data
The data sets supporting the results of this article are
available in the ArrayExpress repository, accession num-
ber E-MEXP-3199.
Additional files
Additional file 1: Human RefSeq mRNAs associated with HIV Tat in
CEM T cells. Transcript IDs, Entrezgene ID, Gene name and Description
of mRNAs bound by HIV Tat in replicate experiments.
Additional file 2: Tat bound RNAs of the KEGG aminoacyl tRNA
biosynthesis pathway. Schematic of the aminoacyl tRNA biosynthesis
pathway defined by the Kyoto Encyclopedia of Genes and Genomes
(KEGG). Proteins encoded by Tat-bound RNAs (from the expanded set of
2000 RNAs) are highlighted in green. Proteins are named by their IUBMB
enzyme nomenclature.
Additional file 3: Location of sequence motifs enriched in
Tat-bound mRNAs. MAST was used to identify the position of
sequences matching each of the motifs (Figure 5). Each of the mRNAs
shown has an E-value less than 0.001. The motif matches shown have a
position p-value less than 0.01. Motif 3 was removed by MAST because it
had a similarity greater than 0.60 with another motif (Motifs 0 and 2).
Additional file 4: HIV infection gene expression data for Figure 6A.
Transcript IDs, Entrezgene ID, Gene name, Description and log2 gene
expression ratios relative to untreated cells at the same timepoint. Data
for genes with multiple probes are averaged and probes filtered for
those exhibiting at least 1 absolute log2 expression ratio above 1.
Additional file 5: Gene Ontology biological process categories
enriched in the sets of genes upregulated during HIV infection. A.
As Figure 6B, except showing genes with functions in an expanded set
of Gene Ontology categories. B. P-values of Gene Ontology biological
process categories enriched (p < 0.001) in the A and B clusters marked in
A. Enrichment of each functional category is specific to only one of the
two clusters.
Additional file 6: Tat RNA binding is not associated with changes in
the abundance of interferon-inducible RNAs. Scatter plot of the
changes in RNA abundance in CEM cells treated with IFNβ (400U/ml
for 4 hours) versus change in RNA abundance in CEM-HA-Tat cells treated
with IFNβ. RNAs associated with Tat by native RNA IP are indicated in
red. RNAs bound by Tat are not differentially regulated by IFNβ
compared with other RNAs and also do not show significant differences
in their response to IFNβ in the presence of Tat.
Additional file 7: CEM HA-Tat gene expression data in Figure 6D.
Transcript IDs, EntrezGene ID, Gene name, Description and log2 gene
expression ratios relative to the parental CEM cell line and the CEM-GFP
cell line. RNAs associated with HIV Tat (by RNA IP) are indicated.
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